This isn't the big fish-oil drug acquisition industry watchers were anticipating. BASF, the German chemicals giant, plans to gobble up Norway's Pronova BioPharma, maker of the active ingredient in GlaxoSmithKline's ($GSK) blockbuster omega-3 drug Lovaza, in a cash buyout valued at NOK 4,845 million or $844 million. Report